Eris Lifesciences stated that its consolidated net profit increased 12 per cent to Rs 101 crore for the third quarter ended December 2021.
The company stated that the revenue stood at Rs 332 crore in the third quarter of the current fiscal as against Rs 310 crore in the year-ago period, Eris Lifesciences said.
''Our focus on building leadership brands in fast-growing therapies coupled with several patent expiration opportunities will enable us to sustain our growth trajectory,'' stated Eris Lifesciences Chairman & Managing Director Amit Bakshi.
(With inputs from PTI)
Delhi Police Arrest Over 130 People In Massive Crackdown On Visa & Passport Fraud Networks
Thane Court Acquits Father-Son Duo In 2022 Murder Case Due To Lack Of Evidence
Will Shah Rukh Khan's KKR Team Get Refund Of ₹ 9.20 Crore After Releasing Mustafizur Rahman? Check Details
Kerala Govt To File Review Petition In SC Against K-TET Verdict Affecting Pre-2010 Teachers
